Guide for Authors
International Immunopharmacology is an interdisciplinary journal devoted to the publication of original scientific papers interrelating immunology and pharmacology. Manuscripts will be considered for publication on the condition that the results reported are based on original research that has not been published elsewhere in any journal or language.
Types of Paper
• Full-length articles are full-length descriptions of original research. The scope may include basic science, clinical results, or applications. These manuscripts will undergo standard review. We emphasize that papers on natural products must meet the following specific criteria: a) any natural extract or drug should be fully characterized and information provided regarding origin - specifically, the "drug" under study must have been fractionated and the active substances within the natural product identified; b) isolation or purification techniques must be described in detail; and c) the authors must state in their paper that the material under study is endotoxin free, including not only natural products, but also all biologics and synthetics used for immunopharmacologic studies. The Editor-in-Chief requests that authors of Natural Product contributions read the guidelines as set out in the Editorial article of International Immunopharmacology volume 6, issue 8 and extended in International Immunopharmacology volume 37, issue 3 both of which are freely accessible online. Many natural products and their isolated biologically active pharmacophores are natural antioxidants: notably flavonoids and more specifically phenols or polyphenols. As many of these antioxidants are "pan-assay interference compounds" (PAINS) with false positive results when studied using in vitro screening assays (J. Nat. Prod. 2016, 79, 616); submissions focused on such mediators are discouraged but not prohibited. Optimally, studies using isolated mediators with antioxidant activity that are scientifically justified and rigorous will generally be considered. We note that in vivo activity is considered encouraging for such studies; although one such pharmacophore, curcumin that has been the focus of more than 120 clinical studies has yet to document any therapeutic benefit (J. Med. Chem. 2017, 60, 1620).
• Short Communications. These are short manuscripts that have important and generally conclusionary data on a specific issue. They should consist of no more than 3000 words with up to an additional 20 references and two tables and/or figures.
• Preliminary Studies/Reports. This section is for the publication of new observations that are promising but have not achieved the stature of a regular article, yet are judged by the reviewers or editorial staff to contribute a novel, important, or useful observation worthy of publication. These reports, including clinical studies on a limited patient population, will generally be brief reports of a single or a few observations or results comprising up to four printed pages including all references and display items; appropriate statistical analyses should be included.
• Reviews are comprehensive appraisals of research and clinical outcomes in a field of current interest. Potential authors are instructed to contact the Editor-in-Chief first regarding topic and suitability. All reviews are subject to the normal review process.
• Invited Commentary. Topical editorials, commentaries, prospective reviews and hypotheses demonstrating acceptable standards of originality. Such articles will only be published following an invitation to the author(s) from an Editor. Other prospective authors should obtain editorial permission before submitting a manuscript. Commentaries (3000 words) will serve as the means for expressing controversial, critical and often personal evaluations of research trends. Commentaries in the form of prospective reviews or hypotheses will be composite presentations of wide-ranging observations from the literature, which should indicate, and possibly stimulate, new directions for potentially rewarding immunopharmacological research.
• Letters to the Editor may be considered at the discretion of the Editors.
• Book Reviews. Books for review may be sent to the Editor-in-Chief. Authors interested in reviewing a particular book should communicate directly with him.
• Meeting/Symposia reports are synopses of meetings and symposia, generally shorter than five journal pages. Please contact the Editor-in-Chief prior to submitting. Reports must be submitted within two weeks of the end of the meeting.
• Special Issues or Thematic Reports are collections of full-length articles and/or reviews on a specific topic. These require approval by the Editor-in-Chief; however, recommendations or suggestions are encouraged.
……
更多详情：
https://www.elsevier.com/journals/international-immunopharmacology/1567-5769/guide-for-authors
